70
Participants
Start Date
April 1, 2017
Primary Completion Date
April 1, 2018
Study Completion Date
April 1, 2018
Folfirinox + cetuximab
Cetuximab 250 mg/m² iv infusion for 2h, Oxaliplatin 85 mg/m² administered as an iv infusion for 2h Elvorine 200 mg/m² administered as an iv infusion for 2h, Irinotecan 180 mg/m² iv infusion, 5FU 400 mg/m2 bolus then 5FU 2,400 mg/m² iv infusion for 46h D1=D15 (12 cycles max)
Institut régional du cancer de Montpellier, Montpellier
Merck Serono International SA
INDUSTRY
Institut du Cancer de Montpellier - Val d'Aurelle
OTHER